8-K: Quipt Home Medical Reports Q4 & FY25 Results

Quipt Home Medical Corp. announced its fourth quarter and fiscal year 2025 financial results, showing strong Q4 revenue growth but a slight annual decline.

Summary

• Revenue for Q4 2025 was $68.3 million, an 11% increase compared to $61.3 million for Q4 2024.
• Sequential organic revenue growth from Q3 2025 was strong at 5%.
• Recurring Revenue for Q4 2025 was 80% of total revenue, driven by growth in the resupply platform.
• Adjusted EBITDA for Q4 2025 was $14.9 million (21.8% of revenues), an 11% increase compared to $13.4 million for Q4 2024.
• Net loss for Q4 2025 was ($3.6) million, or ($0.08) per diluted share, compared to ($2.9) million, or ($0.07) per diluted share for Q4 2024.
• Revenue for fiscal year 2025 was $245.4 million, a slight decrease compared to $245.9 million for fiscal year 2024.
• Adjusted EBITDA for fiscal year 2025 was $55.9 million (22.8% of revenue), a 3% decrease compared to $57.7 million for fiscal year 2024.
• Net loss for fiscal year 2025 was ($10.7) million, or ($0.24) per diluted share, compared to ($6.8) million, or ($0.16) per diluted share for fiscal year 2024.
• Cash flow from operating activities was $37.7 million for the year ended September 30, 2025, compared to $35.4 million for the year ended September 30, 2024.
• Cash on hand was $12.9 million as of September 30, 2025, up from $11.3 million as of June 30, 2025.
• Total credit availability was $12.7 million as of September 30, 2025, with $9.1 million available towards the revolving credit facility and $3.6 million available pursuant to the delayed-draw term loan facility.
• The Net Debt to Adjusted EBITDA Leverage Ratio was 1.8x.
• The customer base increased 10% year over year to 346,000 unique patients served in fiscal year 2025.
• Completed 917,000 unique set-ups/deliveries in fiscal year 2025, an increase of 7% from 854,000 in fiscal year 2024.
• Respiratory resupply set-ups/deliveries increased 1% to 486,000 for the year ended September 30, 2025.

Sentiment

Score: 6

Explanation: While annual results show a slight decline in revenue and EBITDA and increased net loss, the strong Q4 performance, sequential organic growth, and positive management outlook on future consistent growth suggest a turnaround and positive momentum. The conservative leverage ratio is also a positive, but the increased net loss and ongoing legal risk temper the overall sentiment.

Positives

• Strong Q4 2025 revenue growth of 11% to $68.3 million.
• Strong sequential organic revenue growth of 5% from Q3 2025.
• High recurring revenue at 80% of total revenue in Q4 2025, driven by the resupply platform.
• Q4 2025 Adjusted EBITDA increased 11% to $14.9 million.
• Increased cash flow from operating activities to $37.7 million for fiscal year 2025.
• Increased cash on hand to $12.9 million as of September 30, 2025.
• Conservative balance sheet with a Net Debt to Adjusted EBITDA Leverage Ratio of 1.8x.
• Customer base grew 10% year over year to 346,000 unique patients.
• Total unique set-ups/deliveries increased 7% to 917,000.
• Management noted accelerating sequential organic growth throughout the back half of fiscal 2025.

Negatives

• Net loss for Q4 2025 was ($3.6) million, an increase from ($2.9) million in Q4 2024.
• Net loss for fiscal year 2025 was ($10.7) million, an increase from ($6.8) million in FY 2024.
• Fiscal year 2025 revenue saw a slight decrease to $245.4 million from $245.9 million in FY 2024.
• Fiscal year 2025 Adjusted EBITDA decreased 3% to $55.9 million from $57.7 million in FY 2024.
• Diluted loss per share worsened from ($0.07) to ($0.08) in Q4 and from ($0.16) to ($0.24) for FY 2025.

Risks

• Risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy.
• General business and economic conditions in the regions of operation.
• Ability to execute on key priorities, including successful completion of acquisitions, business retention, strategic plans, and attracting/retaining key executives.
• Difficulty integrating newly acquired businesses.
• Low profit market segments.
• Disruptions in or attacks (including cyber-attacks) on information technology, internet, network access or other voice or data communications systems or services.
• Evolution of various types of fraud or other criminal behavior.
• Failure of third parties to comply with their obligations.
• Impact of new and changes to, or application of, current laws and regulations.
• Decline of reimbursement rates.
• Dependence on few payors.
• Possible new drug discoveries.
• Novel business model.
• Dependence on key suppliers.
• Granting of permits and licenses in a highly regulated business.
• Legal proceedings and litigation, including as it relates to the civil investigative demand (CID) received from the Department of Justice.
• Increased competition.
• Changes in foreign currency rates.
• Increased funding costs and market volatility due to market illiquidity and competition for funding.
• Availability of funds and resources to pursue operations.
• Critical accounting estimates and changes to accounting standards, policies, and methods.
• Status as an emerging growth company and a smaller reporting company.
• Occurrence of natural and unnatural catastrophic events or health epidemics or concerns.

Future Outlook

Management anticipates consistent organic growth going forward, driven by a scalable operating platform, disciplined expense management, and the continued expansion of diversified product offerings. They observed accelerating sequential organic growth throughout the back half of fiscal 2025, supported by improving referral activity and a stabilizing product mix across key categories.

Management Comments

• "Our fiscal 2025 performance underscores both the durability of our model and the accelerating momentum we generated through the back half of the year." Gregory Crawford, Chairman and CEO.
• "In the fourth quarter, we delivered strong sequential organic growth, effectively managed industry-wide pressures, and continued scaling our platform." Gregory Crawford, Chairman and CEO.
• "Our results highlight the strength of our core operations and the renewed momentum across the business." Hardik Mehta, Chief Financial Officer.
• "As expected, we saw accelerating sequential organic growth throughout the back half of fiscal 2025, supported by improving referral activity and a stabilizing product mix across key categories." Hardik Mehta, Chief Financial Officer.
• "We anticipate consistent organic growth going forward, driven by our scalable operating platform, disciplined expense management, and the continued expansion of our diversified product offering." Hardik Mehta, Chief Financial Officer.

Industry Context

The company operates in the U.S. home medical equipment market, specializing in end-to-end respiratory care and chronic disease management. The results reflect the company's ability to manage 'industry-wide pressures' and scale its platform, suggesting a resilient business model within this sector. The focus on recurring revenue from resupply platforms aligns with a trend towards subscription-like models in healthcare services, aiming to increase annual revenue per patient by offering multiple services.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry comparison.

Legal Proceedings

• Mention of legal proceedings and litigation, including a civil investigative demand (CID) received from the Department of Justice, as a risk factor.

Stakeholder Impact

• Shareholders: Experienced mixed results with a slight annual decline in revenue and EBITDA, and an increased net loss for the full fiscal year, but strong Q4 momentum and a positive future outlook could signal improvement.
• Patients: The company increased its customer base by 10% to 346,000 unique patients and completed 7% more unique set-ups/deliveries, indicating continued and expanded service provision.
• Employees: Management acknowledged the 'unwavering commitment to operational excellence' of the entire Quipt team, suggesting a stable and valued workforce.

Next Steps

• Continue to expand offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions.
• Increase annual revenue per patient by offering multiple services to the same patient.
• Consolidate patient services to make life easier for the patient.
• Drive consistent organic growth through a scalable operating platform and disciplined expense management.
• Continue the expansion of the diversified product offering.

Key Dates

Recommendation

The company presents a mixed financial picture with a slight annual decline in revenue and Adjusted EBITDA, and an increased net loss for the full fiscal year. However, the strong performance in Q4 2025, including 11% revenue growth and 5% sequential organic growth, along with a conservative leverage ratio and management's positive outlook for consistent future organic growth, suggests a potential turnaround. The ongoing legal proceedings (CID) represent an unquantified risk. Given these mixed signals and the need to observe if the Q4 momentum translates into sustained annual improvement, a 'Hold' recommendation is appropriate for investors to monitor future quarters.

Keywords

Home Medical Equipment, Respiratory Care, Durable Medical Equipment, DME, Healthcare, Financial Results, QIPT, Earnings, Adjusted EBITDA, Revenue, Net Loss, Patient Growth, Resupply Platform